SCHEMBL4759348

SCHEMBL4759348

CN1CCN(c2ccc(N/C=C3/C(=O)Nc4cc(C(=O)c5cccc(NC(=O)c6cccc(Cl)c6)c5)ccc43)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.49
NTRK3 Q16288 1/20 0.49
RAB9A P51151 6/20 0.49
NPC1 O15118 5/20 0.49
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NTRK2 Q16620 3/20 0.47
CSF1R P07333 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
EGFR P00533 1/20 0.45
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
ESR2 Q92731 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
F10 P00742 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4759351 1.00 NTRK1 (0.49) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4757095 0.95 NTRK1 (0.50) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4757094 0.95 NTRK1 (0.50) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4706778 0.93 CSF1R (0.52) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4758071 0.93 CSF1R (0.52) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4757933 0.92 NPC1 (0.52) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4757936 0.92 NPC1 (0.52) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4758073 0.92 NTRK1 (0.55) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4703080 0.92 NTRK1 (0.55) NTRK1NTRK3RAB9ANPC1KMT2A
SCHEMBL4706345 0.91 NTRK1 (0.54) NTRK1NTRK3RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 NTRK1 413/4885NTRK3 418/4885RAB9A 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.